Day: March 18, 2024

The start of 2024 has confirmed much weaker demand in the European heat pump market. To properly deal with this situation in a responsible manner, on February 16th this year we announced that we would be introducing a plan in response that would be aimed at reducing staff and overhead costs, particularly within NIBE Climate Solutions in Europe. We are now entering into negotiations to implement these measures in order to align costs and staffing with the current lower sales volumes, we are also looking to establish the best possible foundations for a well-dimensioned and streamlined organization when the market turns around. After the plan has been implemented, the Group’s staffing in Sweden will be reduced by approx. 340 employees, of which approx. 264 from NIBE AB and 40 from CTC AB. In the rest of European operations, negotiations will...

Tower’s silicon photonics technology to be deployed by Coherent across multiple data rates for high-speed optical transceivers PITTSBURGH, PA, and MIGDAL HAEMEK, Israel, March 18, 2024 – Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and lasers, and Tower Semiconductor (NASDAQ/TASE: TSEM), the leading foundry of high-value analog semiconductor solutions, today announced that Coherent has recognized Tower Semiconductor as an Outstanding Innovation and Technology Supplier for its silicon photonics based optical transceiver products. This prestigious award recognizes Tower’s unwavering long-term commitment to providing the most advanced technology solutions, enabling the development of Coherent’s market-leading multiple data rate nodes for high-speed optical transceivers based on Tower’s PH18 silicon photonics process...

Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC). When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and a favorable safety profile across various preclinical animal models. Additionally, preclinical data will be presented on the novel site-specific proprietary GlycOBI™ ADC platform, demonstrating improved in vivo efficacy and stability in animal model studies. These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 5 to 10, 2024 in San Diego,...

Company announcement no. 11 2024  Group CommunicationsHolmens Kanal 2 – 12DK-1092 København KTel. +45 45 14 56 95 18 March 2024Danske Bank share buy-back programme: Transactions in week 11 On 2 February 2024, Danske Bank A/S announced a share buy-back programme for a total of DKK 5.5 billion, with a maximum of 70 million shares, in the period from 5 February 2024 to 31 January 2025, at the latest, as described in company announcement no. 2 2024. The programme is being carried out under Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbour Rules. The following transactions were made under the share buy-back programme in week 11:  Number of shares VWAP DKK Gross valueDKKAccumulated,...

ST HELIER, Jersey, March 18, 2024 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”) (NYSE AMERICAN: CMCL; AIM: CMCL; VFEX: CMCL) is pleased to announce that Tariro Gadzikwa has joined Caledonia’s Board of Directors as an Independent Non-Executive Director with effect from March 15, 2024. It also announces that Steve Curtis, who retired as Chief Executive Officer of the Company in June 2022 and remained on the Board as a Director in a non-executive capacity since then, has decided to step down from the Board and as such will not be seeking re-appointment as a Director at the next annual general meeting. He will therefore leave the Board with effect from the next annual general meeting of the Company. Mr John Kelly, Chairman of the Board, commented: “I am delighted to...

Company announcement no. 19 / 2024Schindellegi, Switzerland – 18 March 2024 Trifork Holding AG – Weekly report on share buyback On 2 November 2023, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 November 2023 up to and including no later than 31 March 2024. For details, please see announcement no. 17 of 31 October 2023. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 15 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 232,497 treasury shares, corresponding to 1.2% of the share capital. Under the program, the following transactions have been...

Reimbursements deferred by 18 months to start in January 2026 instead of July 2024Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed to extend the interest-only period of its existing loan by eighteen months. Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024. Maturity of this first tranche will remain in the first quarter of 2027. The terms of the second $100 million tranche remain unchanged. Peter Bühler, Chief Financial Officer of Valneva, said, “We greatly appreciate the continued support from Deerfield and OrbiMed. This extension further strengthens our cash position and contributes...